3,4-二氯苯基环丙基甲基酮 | 136906-33-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,4-二氯苯基环丙基甲基酮
• 英文名称: cyclopropyl(3,4-dichlorophenyl)methanone
• 英文别名: Cyclopropyl 3,4-dichlorophenyl ketone；cyclopropyl-(3,4-dichlorophenyl)methanone
• CAS: 136906-33-7
• 化学式: C₁₀H₈Cl₂O
• mdl: MFCD03841239
• 分子量: 215.079
• InChiKey: KDVARTRUFLNVCP-UHFFFAOYSA-N

物化性质

• 沸点：
  334.1±27.0 °C(Predicted)
• 密度：
  1.395±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2914700090

反应信息

• 作为反应物：
  描述：

  3,4-二氯苯基环丙基甲基酮 在 palladium on activated charcoal 噻吩 、 氢气 作用下， 以 甲醇 、 xylene 为溶剂， 反应 6.0h， 生成 Methyl 2-[[cyclopropyl-(3,4-dichlorophenyl)methyl]-formylamino]acetate
  参考文献：
  名称：

  2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

  摘要：

  We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca-flux below 0.01 muM. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.064
• 作为产物：
  描述：

  (10b)cyclopropyl(3,4-dichlorophenyl)methanol 在 重铬酸吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 3,4-二氯苯基环丙基甲基酮
  参考文献：
  名称：

  乙烯基环丙烷的不同氟化反应：开环 1,5-氢氟化反应和保环 1,2-二氟化反应

  摘要：

  据报道，乙烯基环丙烷与不同亲电子试剂的不同氟化反应，可以分别通过开环1,5-氢氟化和环保留1,2-二氟化轻松合成同烯丙基单氟化物和邻位二氟化物。

  DOI：

  10.1002/asia.202300476

文献信息

• Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists
  作者：Arthur Gomtsyan、Robert G. Schmidt、Erol K. Bayburt、Gregory A. Gfesser、Eric A. Voight、Jerome F. Daanen、Diana L. Schmidt、Marlon D. Cowart、Huaqing Liu、Robert J. Altenbach、Michael E. Kort、Bruce Clapham、Phil B. Cox、Anurupa Shrestha、Rodger Henry、David N. Whittern、Regina M. Reilly、Pamela S. Puttfarcken、Jill-Desiree Brederson、Ping Song、Bin Li、Susan M. Huang、Heath A. McDonald、Torben R. Neelands、Steve P. McGaraughty、Donna M. Gauvin、Shailen K. Joshi、Patricia N. Banfor、Jason A. Segreti、Mohamad Shebley、Connie R. Faltynek、Michael J. Dart、Philip R. Kym

  DOI：10.1021/acs.jmedchem.6b00287

  日期：2016.5.26

  of research tools such as selective antagonists. Herein, we provide the first detailed report on the development of potent and selective TRPV3 antagonists featuring a pyridinyl methanol moiety. Systematic optimization of pharmacological, physicochemical, and ADME properties of original lead 5a resulted in identification of a novel and selective TRPV3 antagonist 74a, which demonstrated a favorable preclinical

  瞬态受体电位香草酸3（TRPV3）是具有独特表达模式的Ca 2 + -和Na +-渗透通道。在神经元和非神经元组织（包括背根神经节，脊髓和角质形成细胞）中均发现了TRPV3。最近的研究表明，TRPV3可能在炎症，疼痛感和皮肤疾病中起作用。TRPV3研究一直具有挑战性，部分原因是缺乏诸如选择性拮抗剂之类的研究工具。在本文中，我们提供了有关开发具有吡啶基甲醇部分的有效和选择性TRPV3拮抗剂的第一份详细报告。原始铅5a的药理，理化和ADME特性的系统优化导致鉴定出新型的选择性TRPV3拮抗剂74a，在两种不同的神经性疼痛模型以及利血平中枢性疼痛模型中均显示出良好的临床前特征。
• Glycoside derivatives of 2-(3,4-dichlorobenzoyl)-cycopropane-1-carboxylic acid
  申请人：Newron Pharmaceuticals S.p.A.

  公开号：EP1475385A1

  公开（公告）日：2004-11-10

  The compounds of formula I:    wherein R is a glycoside residue optionally having one or more hydroxy groups alkylated or acylated by C1-C4 alkyl or acyl groups, are long lasting inhibitors of kynurenine 3-monooxygenase (KMO) and potent glutamate (GLU) release inhibitors.

  式I化合物：其中R是糖苷残基，该糖苷残基任选地具有一个或多个羟基，这些羟基被C1-C4烷基或酰基团烷基化或酰基化，是长效的犬尿氨酸3-单加氧酶（KMO）抑制剂和强效的谷氨酸（GLU）释放抑制剂。
• Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines
  申请人：Schering A.G.

  公开号：US05171858A1

  公开（公告）日：1992-12-15

  This invention relates to novel substituted imidazo-[1,5-a]pyridines, most especially novel 8-phenylimidazo-[1,5-a]pyridines. It also relates to novel intermediates and to a novel process for the preparation of certain of these compounds. The compounds of the invention have been found to have significant cardiotonic, antiarrhythmic, hypotensive, CNS stimulant, and other pharmacological effects.

  本发明涉及新型取代咪唑[1,5-a]吡啶，尤其是新型8-苯基咪唑[1,5-a]吡啶。它还涉及新型中间体和一种制备这些化合物的新方法。本发明的化合物已被发现具有显著的心脏强心、抗心律失常、降压、中枢神经系统兴奋和其他药理作用。
• Certain 2-aminomethyl-3-phenyl-pyridine intermediates for certain
  申请人：Schering A.G.

  公开号：US05171859A1

  公开（公告）日：1992-12-15

  This invention relates to novel substituted imidazo[1,5-a]pyridines, most especially novel 8-phenylimidazo[1,5-a]pyridines. It also relates to novel intermediates and to a novel process for the preparation of certain of these compounds. The compounds of the invention have been found to have significant cardiotonic, antiarrhythmic, hypotensive, CNS stimulant, and other pharmacological effects.

  本发明涉及新型的取代咪唑并[1,5-a]吡啶，尤其是新型的8-苯基咪唑并[1,5-a]吡啶。它还涉及新型中间体以及一种制备这些化合物的新型方法。发现本发明的化合物具有显著的心脏强效、抗心律失常、降压、中枢神经系统兴奋剂和其他药理作用。
• Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
  申请人：CHDI Foundation, Inc.

  公开号：US10442782B2

  公开（公告）日：2019-10-15

  Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.

  本文提供了某些化合物或其药学上可接受的盐或原药。还提供了包含至少一种本文所述化合物或其药学上可接受的盐或原药以及一种或多种药学上可接受的载体的药物组合物。描述了治疗对抑制 KMO 活性有反应的某些疾病和失调患者的方法，其中包括向此类患者施用一定量的本文所述的至少一种化合物或其药学上可接受的盐或原药，以有效减少疾病或失调的体征或症状。这些疾病包括神经退行性疾病，如亨廷顿氏病。还描述了治疗方法，包括将本文所述的至少一种化合物或其药学上可接受的盐或原药作为单一活性剂给药，或将本文所述的至少一种化合物或其药学上可接受的盐或原药与一种或多种其它治疗剂联合给药。还提供了筛选能够抑制 KMO 活性的化合物的方法。